{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:06:53Z","timestamp":1791515213762,"version":"4.3.4"},"reference-count":50,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1210\/jc.2017-00867","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T14:01:28Z","timestamp":1496325688000},"page":"2950-2961","source":"Crossref","is-referenced-by-count":90,"title":["Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial"],"prefix":"10.1210","volume":"102","author":[{"given":"Fernando","family":"Bril","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Portillo Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Lomonaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Orsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fermin","family":"Tio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"issue":"1","key":"key\n\t\t\t\t20170807140153_B1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.22603","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management","volume":"49","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"key\n\t\t\t\t20170807140153_B2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.dld.2010.02.004","article-title":"Prevention and treatment of nonalcoholic fatty liver disease","volume":"42","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"9","key":"key\n\t\t\t\t20170807140153_B3","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1210\/jc.2007-0482","article-title":"Liver fat in the metabolic syndrome","volume":"92","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t20170807140153_B4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key\n\t\t\t\t20170807140153_B5","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2337\/dc07-0349","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000282088","article-title":"The role of non-alcoholic fatty liver disease in cardiovascular disease","volume":"28","year":"2010","journal-title":"Dig Dis"},{"key":"key\n\t\t\t\t20170807140153_B7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170807140153_B8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2217\/clp.12.47","article-title":"The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"7","year":"2012","journal-title":"Clin Lipidol"},{"issue":"4","key":"key\n\t\t\t\t20170807140153_B9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"key\n\t\t\t\t20170807140153_B10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.22402","article-title":"Statins in liver disease: a molehill, an iceberg, or neither?","volume":"48","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"key\n\t\t\t\t20170807140153_B11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"2","key":"key\n\t\t\t\t20170807140153_B12","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hep.21248","article-title":"Statins and hepatic steatosis: perspectives from the Dallas Heart Study","volume":"44","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B13","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"LIDO Study Group","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"key\n\t\t\t\t20170807140153_B14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"key\n\t\t\t\t20170807140153_B15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"key\n\t\t\t\t20170807140153_B16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes","volume":"329","year":"2005","journal-title":"Am J Med Sci"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","year":"2007","journal-title":"J Hepatol"},{"issue":"11","key":"key\n\t\t\t\t20170807140153_B18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1365-2036.2006.02926.x","article-title":"A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients","volume":"23","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial","volume":"106","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"key\n\t\t\t\t20170807140153_B20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study","volume":"22","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosis.2005.08.021","article-title":"Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients","volume":"184","year":"2006","journal-title":"Atherosclerosis"},{"issue":"5","key":"key\n\t\t\t\t20170807140153_B22","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Pravastatin in Chronic Liver Disease Study Investigators","year":"2007","journal-title":"Hepatology"},{"issue":"12","key":"key\n\t\t\t\t20170807140153_B23","first-page":"CD008623","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"key\n\t\t\t\t20170807140153_B24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00535-010-0203-y","article-title":"Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH","volume":"45","year":"2010","journal-title":"J Gastroenterol"},{"issue":"10","key":"key\n\t\t\t\t20170807140153_B25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial","volume":"43","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","article-title":"Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"174","year":"2004","journal-title":"Atherosclerosis"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B27","first-page":"39","article-title":"Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study","volume":"16","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"issue":"12","key":"key\n\t\t\t\t20170807140153_B28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1155\/2003\/857869","article-title":"Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis","volume":"17","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"key\n\t\t\t\t20170807140153_B29","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.metabol.2016.10.004","article-title":"Reply to \u201cstatins and non-alcoholic steatohepatitis\u201d","volume":"66","year":"2017","journal-title":"Metabolism"},{"issue":"5","key":"key\n\t\t\t\t20170807140153_B30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","year":"2016","journal-title":"Ann Intern Med"},{"issue":"19","key":"key\n\t\t\t\t20170807140153_B31","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170807140153_B32","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.","DOI":"10.2337\/dc15-S003"},{"issue":"9","key":"key\n\t\t\t\t20170807140153_B33","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"key\n\t\t\t\t20170807140153_B34","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"key\n\t\t\t\t20170807140153_B35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","year":"2011","journal-title":"Hepatology"},{"issue":"25","key":"key\n\t\t\t\t20170807140153_B37","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"key\n\t\t\t\t20170807140153_B38","first-page":"CD004371","article-title":"Interventions to improve adherence to lipid lowering medication","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170807140153_B39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.amjmed.2005.09.003","article-title":"Statin use in a \u201creal-world\u201d clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial","volume":"118","year":"2005","journal-title":"Am J Med"},{"issue":"5","key":"key\n\t\t\t\t20170807140153_B40","doi-asserted-by":"crossref","first-page":"e0155228","DOI":"10.1371\/journal.pone.0155228","article-title":"Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study","volume":"11","year":"2016","journal-title":"PLoS One"},{"issue":"9976","key":"key\n\t\t\t\t20170807140153_B41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"key\n\t\t\t\t20170807140153_B42","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"NASH CRN","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"key\n\t\t\t\t20170807140153_B43","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease","volume":"61","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"key\n\t\t\t\t20170807140153_B45","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the Statin Liver Safety Task Force: 2014\u00a0update","volume":"8","author":"The National Lipid Association\u2019s Statin Safety Task Force","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"6","key":"key\n\t\t\t\t20170807140153_B46","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key\n\t\t\t\t20170807140153_B47","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/01.RES.0000268411.49545.9c","article-title":"Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1\/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages","volume":"100","year":"2007","journal-title":"Circ Res"},{"issue":"7","key":"key\n\t\t\t\t20170807140153_B48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjp.0706260","article-title":"Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4","volume":"145","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t20170807140153_B49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","year":"2004","journal-title":"Hepatology"},{"issue":"9972","key":"key\n\t\t\t\t20170807140153_B50","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"NASH Clinical Research Network","year":"2015","journal-title":"Lancet"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/8\/2950\/19452828\/jc.2017-00867.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T15:31:54Z","timestamp":1503588714000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jcem\/article\/102\/8\/2950\/3859972\/Liver-Safety-of-Statins-in-Prediabetes-or-T2DM-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,6,1]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-00867","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}